Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6310720 | 1.00 | CHRM2 (0.48) | CHRM2SLC6A12F10SIGMAR1CHRNB2 | |
| SCHEMBL6306139 | 0.90 | CHRM2 (0.50) | CHRM2F10SIGMAR1CHRNB2CHRNA7 | |
| SCHEMBL6306135 | 0.90 | CHRM2 (0.50) | CHRM2F10SIGMAR1CHRNB2CHRNA7 | |
| SCHEMBL6311169 | 0.87 | RAB9A (0.52) | CHRM2SIGMAR1MAPTHCRTR2 | |
| SCHEMBL6311171 | 0.87 | RAB9A (0.52) | CHRM2SIGMAR1MAPTHCRTR2 | |
| SCHEMBL6310906 | 0.86 | CHRNA7 (0.48) | CHRM2F10SIGMAR1CHRNB2CHRNA7 | |
| SCHEMBL6310911 | 0.86 | CHRNA7 (0.48) | CHRM2F10SIGMAR1CHRNB2CHRNA7 | |
| SCHEMBL6311237 | 0.84 | SIGMAR1 (0.53) | F10SIGMAR1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6311232 | 0.84 | SIGMAR1 (0.53) | F10SIGMAR1CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL6306114 | 0.84 | GRM5 (0.49) | F10SIGMAR1CHRNB2CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977265-B2 | Piperidine CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2005-12-20 | — | — | US | disclosed |
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | CCR1, CCR3, CCRL2 | CHRM2 612/4885SLC6A12 4663/4885F10 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.